Facebook
X
LinkedIn
ForwardJournal Review in Colorectal Surgery: Total Neoadjuvant Therapy in Rectal Cancer
- The treatment for locally advanced rectal cancer has undergone numerous changes and is now used routinely in clinical practice. Please join us in a thorough discussion of current evidence and ongoing research of total neoadjuvant therapy in locally advanced rectal cancer with leaders in the field including Drs J. Joshua Smith, Julio Garcia-Aguilar, Emmanouil Fokas, and Benjamin Schlechter
Target Audience
- Nurses
- Nurse Practitioners
- Physicians
- Physician Assistants
Learning Objectives
- Defining locally advanced rectal cancer (LARC) and describe the clinical staging that qualifies patients for total neoadjuvant therapy (TNT).
- Explaining the rationale for transitioning from traditional chemoradiotherapy (CRT) plus surgery to total neoadjuvant therapy in rectal cancer management.
- Comparing the designs, treatment regimens, and long-term outcomes of major TNT trials including RAPIDO, PRODIGE-23, OPRA, and CAO/ARO/AIO-12/16.
- Evaluating organ preservation strategies—such as the watch-and-wait approach—after TNT and identify which patients are appropriate candidates based on clinical or near-complete response.
- Summarizing emerging research directions including integrating of circulating tumor DNA (ctDNA) in surveillance and response prediction
- Summarizing emerging research directions including the role of immunotherapy in mismatch repair proficient (MSS) and deficient (dMMR) tumors.
Virtual, NC
United States
- Dr. Janet Alvarez
- Dr. Wini Zambare
- Dr. Phil Bauer
- Dr. J. Joshua Smith
- Julio Garcia-Aguilar, MD, PhD
- Benno C. Schmidt Chair in Surgical Oncology
- Benjamin Schlechter, MD
- Emmanouil Fokas, MD, DPhil
- AMA PRA Category 1 Credit(s)
- ANCC
- Attendance
- JA Credit - AH
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 ANCC
- 1.00 Attendance
- 0.10 IACET CEU